Fox Rothschild Transactions Named Among Finalists for M&A Advisor Awards

September 26, 2016 – Press Releases

Fox Rothschild LLP is pleased to announce that two transactions handled by the firm’s attorneys have been listed as finalists in several categories for The M&A Advisor’s 15th Annual M&A Advisor Awards. The deals selected were:

  • Spinoff of J. Alexander’s Holdings, Inc.
    • Financials Deal of the Year
  • Acquisition of Epic Pharma, LLC
    • Health Care and Life Sciences Deal of the Year (Over $100 million)
    • Cross-Border Deal of the Year

These annual awards recognize the leading dealmakers, firms and transactions as selected by an independent panel of judges. The winners will be announced at a special awards gala on November 9 at the Annual M&A Advisor Summit in New York.

Deal Details

Spinoff of J. Alexander’s Holdings, Inc.

A team of Fox Rothschild public companies attorneys represented Fidelity National Financial Ventures (NYSE: FNFV) on the spinoff of its J. Alexander’s Holdings, Inc. (NYSE: JAX) subsidiary in a highly valued transaction. The newly spun-off public company is now listed on The New York Stock Exchange.

Fox attorneys collaborated with management of J. Alexander’s Holdings, Inc. to focus on the discrete aspects of the structure to analogize the profits interest to a stock option in that both features offer their respective holders an opportunity to share in a company’s growth without granting such holders direct equity in the company.

In addition, the multi-office team for this transaction included Vincent A. Vietti and Zev M. Bomrind.

Acquisition of Epic Pharma, LLC

A team of Fox Rothschild attorneys represented PuraCap Pharmaceutical LLC, a New Jersey-based pharmaceutical company, and its parent company Humanwell Healthcare Group Co., Ltd. (SHA: 600079), a China-based life sciences company, in their US$550 million acquisition of Epic Pharma, LLC.

The acquisition is notable for several reasons.  It represents a significant commitment by a Chinese company to the development and manufacture of generic pharmaceuticals in the U.S., and more particularly to the New York City region.  It provides a large generic product portfolio for Humanwell and PuraCap.  The transaction closed remarkably quickly, less than 60 days after signing.  Finally, the financing was provided by a non-U.S. bank, New York Branch of China Merchants Bank served as the Bookrunner and Mandated Lead Arranger in this transaction.  For this combination of reasons, this acquisition represents a significant milestone for foreign direct investment by Chinese companies.

Fox’s team included Loren David Danzis, Jianming Jimmy Hao, Ph.D., Paul B. Edelberg, Matthew R. Kittay, Andrew M. Halbert, and Michael S. Bookbinder and Jeffrey H. Nicholas.